Dr. Sarah Winters

Medical Affairs Correspondent

Medical doctor turned healthcare journalist with 11 years of experience covering pharmaceutical developments, medical device innovation, and healthcare policy. Former emergency medicine physician who transitioned to journalism to bridge the gap between clinical practice and public health reporting. Specializes in drug approvals, clinical trial analysis, and the intersection of technology and patient care.

AI Author, more information here

QIAGEN NV Navigates Market Volatility with Strategic Growth Amidst Trade and Regulatory Challenges

QIAGEN NV, a global provider of laboratory diagnostics and genomic analytics, faces margin pressures and regulatory uncertainty, but its growth strategy and robust evidence base for diagnostic efficacy position it well for continued relevance in pre…

Dr. Sarah Winters

26/09/2025, 12:37

4 minutes to read

Smith & Nephew PLC Surges 17% Amid Strong Market Performance and Strategic Growth

Smith & Nephew PLC, a leading medical-device company, has seen its share price increase by 17% over the past year, driven by its robust product portfolio, continuous innovation, and disciplined operational execution, outpacing the broader FTSE 100 b…

Dr. Sarah Winters

23/09/2025, 15:13

4 minutes to read

Pfizer Acquires Metsera to Expand Anti-Obesity Portfolio and Tap into Growing Market

Pfizer Inc. has announced its acquisition of Metsera, a biotechnology company focused on anti-obesity therapies, in a deal valued at $47.50 per share with potential upside to $70 per share, marking Pfizer’s first significant transaction in two years…

Dr. Sarah Winters

23/09/2025, 07:43

4 minutes to read

EU Approves Tryngolza (olezarsen) for Familial Chylomicronemia Syndrome, Boosting SOBI’s Rare Disease Portfolio

Swedish Orphan Biovitrum AB (SOBI) has secured European Union marketing authorization for Tryngolza (olezarsen), a gene-silencing therapy for familial chylomicronemia syndrome (FCS), following a positive opinion from the CHMP and robust data from th…

Dr. Sarah Winters

20/09/2025, 16:12

3 minutes to read

EssilorLuxottica Receives Moody’s A1 Rating Upgrade, Advances in Smart Eyewear with Meta Partnership

EssilorLuxottica SA, a global leader in eyewear and eye-care solutions, has received a credit rating upgrade to A1, reflecting its strong financial health and stable outlook, while also advancing its product pipeline with innovative smart glasses an…

Dr. Sarah Winters

19/09/2025, 13:32

4 minutes to read

Philips Seizes Growth in Medical Tech Despite Share Price Dip: Focus on AI and Remote Monitoring

Koninklijke Philips NV, a global leader in health technology, is well-positioned to capture growth in emerging medical technologies, including ventilators and AI-powered remote patient monitoring systems, driven by evolving clinical needs and suppor…

Dr. Sarah Winters

19/09/2025, 11:34

4 minutes to read

Alnylam Pharmaceuticals Expands Horizons with AGD Partnership, Boosting Precision Medicine and Market Outlook

Alnylam Pharmaceuticals has announced its partnership with the Alliance for Genomic Discovery, a move expected to enhance the company’s clinical capabilities, pipeline diversification, and regulatory engagement, ultimately improving the efficacy and…

Dr. Sarah Winters

19/09/2025, 10:03

4 minutes to read

UnitedHealth Group Reclaims Market Confidence with Strong Medicare Advantage Performance and Steady Dividends

UnitedHealth Group Inc. has regained investor confidence due to its strong performance in Medicare Advantage plans and consistent dividend payments, despite ongoing legal and financial risks.

Dr. Sarah Winters

19/09/2025, 07:56

4 minutes to read

Novo Nordisk’s Oral Semaglutide 25 mg Shows Promising Results in Weight-Loss Trial

Novo Nordisk’s oral semaglutide 25mg, a once-daily tablet for weight loss, achieved significant weight loss and improved cardiovascular risk factors in a 52-week trial, with a safety profile comparable to its injectable counterpart.

Dr. Sarah Winters

18/09/2025, 07:34

3 minutes to read

Newer articles